Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding ; volume:07 ; number:03 ; year:2023 ; pages:e206-e216
TH open ; 07, Heft 03 (2023), e206-e216
- Beteiligte Personen und Organisationen
-
Caroti, Kimberly Snow
Becattini, Cecilia
Carrier, Marc
Cohen, Alexander T.
Ekbom, Anders
Khorana, Alok A.
Lee, Agnes Y.Y.
Brescia, Christopher
Abdelgawwad, Khaled
Psaroudakis, George
Rivera, Marcela
Schaefer, Bernhard
Brobert, Gunnar
Coleman, Craig I.
- DOI
-
10.1055/s-0043-1770783
- URN
-
urn:nbn:de:101:1-2023082411172465364893
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Caroti, Kimberly Snow
- Becattini, Cecilia
- Carrier, Marc
- Cohen, Alexander T.
- Ekbom, Anders
- Khorana, Alok A.
- Lee, Agnes Y.Y.
- Brescia, Christopher
- Abdelgawwad, Khaled
- Psaroudakis, George
- Rivera, Marcela
- Schaefer, Bernhard
- Brobert, Gunnar
- Coleman, Craig I.
Ähnliche Objekte (12)
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Safety of Apixaban for Cancer-Associated Thrombosis
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
Innovative Antithrombotika : Ticagrelor, Prasugrel, Elinogrel, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Vorapaxar, Atopaxar
Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?
Extended Anticoagulant Treatment with Full-or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: the API-CAT Study
Shorter hospital stays in epistaxis patients taking Rivaroxaban and Apixaban vs. Phenprocoumon
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
ADPKD, COVID-19, and Apixaban: The Treacherous Intracystic Bleeding – A Letter on Apixaban Causing Hepatic Cystic Bleeding by Shehi et al.
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Update on Cancer-Associated Venous Thromboembolism in Children
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Safety of Apixaban for Cancer-Associated Thrombosis
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
Innovative Antithrombotika : Ticagrelor, Prasugrel, Elinogrel, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Vorapaxar, Atopaxar
Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?
Extended Anticoagulant Treatment with Full-or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: the API-CAT Study
Shorter hospital stays in epistaxis patients taking Rivaroxaban and Apixaban vs. Phenprocoumon
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
ADPKD, COVID-19, and Apixaban: The Treacherous Intracystic Bleeding – A Letter on Apixaban Causing Hepatic Cystic Bleeding by Shehi et al.
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Update on Cancer-Associated Venous Thromboembolism in Children
Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Safety of Apixaban for Cancer-Associated Thrombosis
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
Innovative Antithrombotika : Ticagrelor, Prasugrel, Elinogrel, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Vorapaxar, Atopaxar
Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?
Extended Anticoagulant Treatment with Full-or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: the API-CAT Study
Shorter hospital stays in epistaxis patients taking Rivaroxaban and Apixaban vs. Phenprocoumon
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
ADPKD, COVID-19, and Apixaban: The Treacherous Intracystic Bleeding – A Letter on Apixaban Causing Hepatic Cystic Bleeding by Shehi et al.
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Update on Cancer-Associated Venous Thromboembolism in Children